Shots:

• The first patient has been dosed in a P-II study evaluating the safety & preliminary efficacy of onvansertib + Irinotecan and 5-FU in ~40 patients as a 2L treatment for metastatic PDAC who have failed 1L gemcitabine-based therapy across 6 sites in the US
• The 1EPs of the study is ORR and 2EPs include DoR- m-OS- ORR in patients receiving more than two treatment cycles- DCS- and assessment of KRAS allelic burden in liquid biopsies as measured by ctDNA
• The ongoing P-II trial of onvansertib + irinotecan and 5-FU for KRAS-mutated mCRC showed clinical benefit and improve outcomes. Additionally- the company is also expected the similar results in PDAC trial

  | Ref: PR Newswire | Image: Cardiff Oncology